Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/AQST/Capital expenditures

Aquestive Therapeutics, Inc. (AQST) Capital expenditures 2017–2025

Aquestive Therapeutics, Inc. (AQST) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.

$562,000FY2025 · since FY2017: $2.1M → $562,000
171819202122232425
Fiscal yearValueYoY
FY2025$562,000+253.5%
FY2024$159,000-84.0%
FY2023$995,000-2.8%
FY2022$1.0M+12.2%
FY2021$913,000+76.6%
FY2020$517,000-22.0%
FY2019$663,000-63.7%
FY2018$1.8M-11.8%
FY2017$2.1M—

Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.

Source: SEC XBRL filings · For reference only · Not investment advice

More AQST financial trends

AQST RevenueAQST Net incomeAQST Net marginAQST Gross profitAQST Gross marginAQST Operating incomeAQST Operating marginAQST Operating cash flowAQST Free cash flowAQST Return on equityAQST Stock buybacksAQST Dividends paidAQST Total assetsAQST Total liabilitiesAQST Shareholders’ equityAQST overview →